Journal profile · ONCOLOGY
Future Oncology
ISSN 1479-6694 · eISSN 1744-8301 · Future Medicine Ltd. · ENGLAND · Monthly · Founded 2005
Future Oncology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.18; hybrid open access; median 144 days to acceptance (114 articles, last 24 months); 351 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Future Oncology is published by Future Medicine Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers and Cancer Genomics and Diagnostics, together about 23.5% of its articles. Its main subfields are Pulmonary and Respiratory Medicine and Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
Source: LetPub
Research area (LetPub): ONCOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Treatments and MutationsMedicine9.7%
- Cancer Immunotherapy and BiomarkersMedicine7.9%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology6%
- Lung Cancer Research StudiesMedicine5.2%
- Colorectal Cancer Treatments and StudiesMedicine5.1%
- HER2/EGFR in Cancer ResearchMedicine5%
- Prostate Cancer Treatment and ResearchMedicine4.8%
- Gastric Cancer Management and OutcomesMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.18LetPub ·
- CiteScore 2026-06
- 4.9LetPub ·
- SJR 2026-06
- 1.23LetPub ·
- SNIP 2026-06
- 0.79LetPub ·
- h-index
- 60LetPub ·
- h-index
- 112OpenAlex ·
- i10-index
- 2,498OpenAlex ·
- 2-year mean citedness
- 2.9OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 23.77%LetPub ·
Volume
- Articles per year
- 290LetPub ·
Articles by year OpenAlex count · 5,673 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 199 | 185 | 68 |
| 2025 | 351 | 328 | 762 |
| 2024 | 307 | 290 | 1,657 |
| 2023 | 298 | 164 | 2,243 |
| 2022 | 353 | 185 | 4,041 |
| 2021 | 432 | 192 | 6,813 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
144 daysMedian, submission to acceptance · P25–P75 106 days – 219 days
- Acceptance to online
- median 15 days (114 articles)
- Submission to online
- median 163 days
- Sample
- 114 articles with submission and acceptance dates (649 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Future Medicine Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 2005
- ISSN
- 1479-6694
- Electronic ISSN
- 1744-8301
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Future Oncology
What CAS zone is Future Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Future Oncology is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Future Oncology?
The latest impact factor listed by LetPub is 3.18; CiteScore 4.9, h-index 112.
How long does peer review take at Future Oncology?
Based on the dates recorded on 114 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 144 days (interquartile range 106–219 days); authors report an average review time of 4–8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Future Oncology?
According to LetPub and DOAJ records, Future Oncology is indexed in SCIE and Scopus.
Is Future Oncology open access, and what is the APC?
Future Oncology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .